This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Thomas Jefferson University. Active years: 2017.
Company Filing History:
Years Active: 2017
Title: Leonard Edelstein: Innovator in PAR4 Inhibitor Therapy
Introduction
Leonard Edelstein is a notable inventor based in Philadelphia, PA (US). He has made significant contributions to the field of medical research, particularly in the development of therapies targeting specific genetic polymorphisms. His work focuses on improving patient outcomes through personalized medicine.
Latest Patents
Edelstein holds a patent for a PAR4 inhibitor therapy designed for patients with PAR4 polymorphism. The patent outlines methods for determining whether a PAR4 inhibitor should be administered to a human subject. Specifically, it details the administration of a PAR4 inhibitor to subjects with a 'G' allele for a single-nucleotide polymorphism (SNP) at rs773902, while withholding the treatment from those with an 'A' allele for the same SNP. This innovative approach utilizes a genotyping assay to identify the SNP, thereby enhancing the precision of treatment.
Career Highlights
Leonard Edelstein is affiliated with Thomas Jefferson University, where he conducts research and collaborates with other experts in the field. His work has garnered attention for its potential to revolutionize treatment protocols for patients with specific genetic markers.
Collaborations
Edelstein has worked alongside esteemed colleagues such as Paul F Bray and Michael Holinstat. Their combined expertise contributes to the advancement of research in the area of PAR4 inhibitors and personalized medicine.
Conclusion
Leonard Edelstein's innovative work in PAR4 inhibitor therapy exemplifies the impact of targeted medical treatments on patient care. His contributions to the field continue to pave the way for advancements in personalized medicine.